The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Molecularly targeted therapy is a kind of remedy that uses drugs or other compounds to recognize and identify exact types of cancer units with less harm to normal cells by hindering with exact targeted molecules required for carcinogenesis and tumor development rather than by simply hindering with all quickly dividing cells e.g. traditional Chemotherapy but radiotherapy is not advised a 'targeted therapy' despite its often being directed at the tumors. Targeted cancer therapies are expected to be more effective than current treatments and less harmful to normal cells. There are targeted therapies for multiple myeloma, prostate cancerous disease, breast cancerous disease, melanoma lymphoma, and other cancers. The major classes of targeted therapy are small molecules and monoclonal antibodies. Some targeted therapy block the activity of certain proteins, enzymes, or other substances which are involved in the development and disperse of cancerous cells. Other types of targeted therapy helps the immune system to kill the cancerous cells or deliver toxic compounds exactly to cancerous cells and kills them. As the goal being recognized, the treatment must be evolved. Most targeted therapy is either monoclonal antibodies or small-molecule drugs. Targeted therapy may have less side consequences than other kinds of cancer remedy. Small-molecule drugs are normally able to diffuse into units and can act on goals that are found interior the cell. Most monoclonal antibodies will not penetrate the cellâs plasma membrane and are administered against goals that are outside units or on the cell surface.
Last date updated on April, 2021